| 李冬云,黄山,陈信义,许亚梅,侯丽.复方浙贝颗粒对难治性急性白血病患者生存期影响的临床观察[J].,2012,32(7):889-891 |
| 复方浙贝颗粒对难治性急性白血病患者生存期影响的临床观察 |
| Clinical Observation of Compound Zhebei Granule in Improving the Survival Time of Refractory Acute Leukemia Patients |
| |
| DOI： |
| 中文关键词: 复方浙贝颗粒 难治性急性白血病 中位持续缓解时间 中位生存时间 |
| 英文关键词:Compound Zhebei Granule refractory acute leukemia the median sustained remission time the median survival time |
| 基金项目:国家科技支撑计划资助项目(No.2006BAI04A18) |
|
| Hits: 1327 |
| Download times: 7 |
| 中文摘要: |
| 目的观察以复方浙贝颗粒为主的中医干预治疗方案,对难治性急性白血病( RAL) 患者持续缓解时间、中位生存时间,以及复发率、病死率等方面的影响。方法对围化疗期实施中医干预治疗方案联合西医标准化疗的 RAL,于 1 个标准化疗疗程结束后取得完全缓解的受试者 57 例进行随访,了解其持续缓解时间、生存时间、复发率及病死率等情况。结果进入统计病例共 41 例,其中浙贝组 20 例,对照组 21 例。浙贝组和对照组的中位持续缓解时间分别为 172、115 天; 中位生存期分别为 363、201 天。浙贝组在 3、6 个月内、1 年内及总复发率分别为 30. 0%、50. 0%、70. 0%、90. 0%,均低于对照组的 42. 8%、76. 2%、90. 5%、90. 5% 。浙贝组的病死率为 80. 0% ,比对照组( 85. 7% ) 降低 5. 7% 。结论复方浙贝颗粒具有延长 RAL 患者持续缓解时间,提高患者生存时间,降低患者复发率以及病死率等趋势。 |
| 英文摘要: |
| Objective To observe the effects of Compound Zhebei Granule(CZG) as the main intervention and treatment protocol on the sustained remission time,the median survival time,the relapse rate,and the mortality rate of refractory acute leukemia(RAL) patients.Methods The RAL subjects,who were completely released after one standard chemotherapeutic course of the National Support Scheme(Chinese medicine interventions and standard chemotherapy of Western medicine in the peri-chemotherapy) were followed-up to get knowledge of the sustained remission time,the survival time,the relapse rate,and the morbidity.Results Totally 41 patients were finally accounted into the statistics,20 in the treatment group and 21 in the control group.The sustained remission time was 172 days in the treatment group and 115 days in the control group,the median survival time was 363 days and 201 days respectively.The relapse rate of the treatment group within 3 months,6 months,1 year,and the total relapse rate was 30.0%,50.0%,70.0%,and 90.0%,respectively,lower than that of the control group(being 42.8%,76.2%,90.5%,90.5%,respectively).The mortality rate of the treatment group was 80.0%,5.7% lower than that of the control group(85.7%).Conclusion CZG could lengthen the sustained remission time for RAL patients,elevate their survival time,and reduce the relapse rate and the mortality rate. |
| View Full Text View/Add Comment Download reader |
|
|
|
